Risk factors for early anthracycline clinical cardiotoxicity in children: The pediatric oncology group experience

Progress in Pediatric Cardiology

Volumn 8, Issue 2, 1997, Pages 83-90

  Krischer, J P ^a   Cuthbertson, D D ^a   Epstein, S ^a   Goorin, A M ^b,c,d   Epstein, M L ^e,f   Lipshultz, S E ^g,h  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STRONG MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Cancer; Cardiotoxicity; Congestive heart failure; Pediatric

Indexed keywords

AMSACRINE; ANTHRACYCLINE;

ADOLESCENT; ARTICLE; CANCER; CARDIOTOXICITY; CHILD; CONGESTIVE HEART FAILURE; ETHNIC DIFFERENCE; FEMALE; HEART FUNCTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEGRO; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SUDDEN DEATH; TRISOMY 21;

EID: 0031411098     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(98)00005-8     Document Type: Article

References (55)

1. Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 14:1986;211-215.
2. Smith MA, Ungerleider RS, Hurwitz MEet al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 83:1991;1460-1470.
3. Burgert EO, Nesbit ME, Garnsey LAet al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol. 8:1990;1514-1524.
4. Von Hoff DD, Layard M, Basa Pet al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91:1979;710-717.
5. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med. 62:1977;200-207.
6. Minow RA, Benjamin RS, Lee ET, Gottleib JA Adriamycin cardiomyopathy risk factors. CA. 39:1977;1397-1402.
7. Minow RA, Benjamin RS, Gottleib JA Adriamycin (NSC-123127) cardiomyopathy - an overview with determination of risk factors. Cancer Chemother Rep. 6:1975;195-201.
8. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE Clinical Cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol. 15:1997;1544-1552.
9. Hausdorf G, Mork G, Beron Get al. Long-term doxorubicin cardiotoxicity in childhood: Non-invasive evaluation of the contractile state and diastolic filling. Br Heart J. 60:1988;309-315.
10. Goorin AM, Chauvenet AR, Perez-Atayde AR, Cruz J, McKone R, Lipshultz SE Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr. 116:1990;144-147.
11. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 324:1991;808-815.
12. Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 337:1991;816-818.
13. Weesner KM, Bledsoe M, Chauvenet A, Wofford M Exercise echocardiography in the detection of anthracycline cardiotoxicity. CA. 68:1991;435-438.
14. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 266:1991;1672-1677.
15. Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 19:1992;394-401.
16. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 70:1992;73-77.
17. Anon Childhood cancer, anthracyclines, and the heart. Lancet. 339:1992;1388-1389.
18. Larsen RL, Barber G, Heise CT, August CS Exercise assessment of cardiac function in children and young adults before and after bone marrow transplantation. Pediatrics. 89:1992;722-729.
19. Green DM Effects of treatment for childhood cancer on vital organ systems. Cancer. 71:1993;3299-3305.
20. Leandro J, Dyck J, Poppe Det al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol. 74:1994;1152-1156.
21. Lipshultz SE, Lipsitz SR, Mone SMet al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. New Engl J Med. 332:1995;1738-1743.
22. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I Cardiac function in Wilms' tumor survivors. J Clin Oncol. 13:1995;1546-1556.
23. Lipshultz SE, Colan SD. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. In: Bricker JT, Green DM, DiAngeo G, editors. Long term complications of treatment of children and adolescents for cancer. Philadelphia: Wiley-Liss, 1993:45-62.
24. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD Monitoring for anthracycline cardiotoxicity. Pediatrics. 93:1994;433-437.
25. Burrows FA, Hickey PR, Colan S Perioperative complications in patients with anthracycline chemotherapeutic agents. Can J Anaesth. 32:1985;144-157.
26. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 9(7):1991;1215-1223.
27. Isberg B, Paul C, Jonsson L, Svahn U Myocardial toxicity of high-dose cyclophosphamide in rabbits treated with daunorubicin. Cancer Chemother Pharmacol. 28(3):1991;171-180.
28. Ayash LJ, Wright JE, Tretyakov Oet al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 10(6):1992;995-1000.
29. Steinherz LJ, Steinherz PG, Mangiacasale D, Tan C, Miller DR Cardiac abnormalities after AMSA administration. Cancer Treat Rep. 66(3):1982;483-488.
30. Weiss RB, Grillo-Lopez AJ, Marsoni S, Posada JG Jr., Hess F, Ross BJ Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol. 4(6):1986;918-928.
31. Tan CT, Hancock C, Steinherz PGet al. Phase II study of 4′-(9-acridiny-lamino) methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma. Cancer Res. 42(4):1982;1579-1581.
32. Krischer J, Land VJ, Civin CI, Ragab AH, Mahoney DH, Frankel LS Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. Cancer. 54(2):1984;207-210.
33. Kaplan EL, Meier P Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
34. Peto R, Peto J Asymptotically efficient rank invariant test procedures. J R Stat Soc. 135:1972;185-198.
35. Cox DR Regression models and life-tables. J R Stat Soc. 34:1972;187-220.
36. Altman DG, Lausen B, Sauerbrei W, Schumacher M Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. JNCI. 86:1994;829-835.
37. SAS/STAT User's Guide, vol. 2. Version 6, 4th ed. 1990. SAS Institute, Cary NC. Chapter 26.
38. Matthys D, Verhaaren H, Benoit Y, Laureys G, DeNaeyer A, Craen M Gender difference in aerobic capacity in adolescents after cure from malignant disease in childhood. Acta Pediatr. 82:1993;459-462.
39. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 21:1993;477-479.
40. Frisancho AR Triceps skin fold and upper arm muscle size norms for assessment of nutritional status. Am J Clin Nutr. 27:1974;1052-1058.
41. Tanner JM, Whitehouse RH Revised standards for triceps and subscapular skinfolds in British children. Arch Dis Child. 50:1975;142-145.
42. Lee YT, Chan KK, Harris PA Tissue disposition of doxorubicin in experimental animals. Med Pediatr Oncol. 10:1982;259-267.
43. Piazza E, Natale N, Trabattoni Aet al. Plasma and tissue distribution of adriamycin in patients with pelvic cancer. Tumori. 67:1981;533-537.
44. Rodvold KA, Rushing DA, Tewksbury DA Doxorubicin clearance in the obese. J Clin Oncol. 6:1988;1321-1327.
45. Bradley G, Georges E, Ling V Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol. 145:1990;398-408.
46. Dobbs NA, Tewlves CJ, Gillies H, James CA, Harper PG, Rubens RD Gender effects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 36:1995;473-476.
47. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B Variability in the pharmacokinetics of epirubrein: a population analysis. Cancer Chemother Pharmacol. 29:1992;391-395.
48. Eysmann SB, Douglass PS. Coronary heart disease: therapeutic principles. In: Douglass PS, editor. Cardiovascular health and disease in women. Philadelphia: W.B. Saunders, 1993:57.
49. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
50. Wenger NK, Speroff L, Packard B Cardiovascular health and disease in women. N Engl J Med. 329:1993;247-256.
51. Couglin SS, Szklo M, Baughman K, Pearson TA The epidemiology of idiopathic dilated cardiomyopathy in a biracial community. Am J Epidemiol. 131:1990;48-56.
52. Couglin SS, Labenberg JR, Tefft MC Black-white differences in idiopathic dilated cardiomyopathy: the Washington DC dilated cardiomyopathy study. Epidemiology. 4:1993;165-172.
53. Couglin SS, Neaton JD, Sengupta A, Kuller LH Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the multiple risk factor intervention trial. Am J Epidemiol. 139:1994;166-172.
54. Couglin SS, Gottdiener JS, Baughman KL Black-white differences in mortality in idiopathic dilated cardiomyopathy: the Washington, DC dilated cardiomyopathy study. J Natl Med Assoc. 86:1994;583-591.
55. Khoury M, Erickson D Improved ascertainment of cardiovascular malformations in infants with Down's syndrome, Atlanta, 1968 through 1989. Am J Epidemiol. 136:1992;1457-1464.